Second-generation TKI dasatinib inhibits proliferation of mesenchymal stem cells and osteoblast differentiation in vitro

Leukemia

Volumn 24, Issue 7, 2010, Pages 1357-1359

  Jonsson S ^a,b   Hjorth Hansen, H ^a   Olsson, B ^b   Wadenvik, H ^b   Sundan, A ^a   Standal, T ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; DASATINIB; IMATINIB; MESSENGER RNA; TRANSCRIPTION FACTOR OSTERIX; TRANSCRIPTION FACTOR RUNX2; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

BONE DENSITY; BONE GROWTH; BONE TURNOVER; CELL DIFFERENTIATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HYPOPHOSPHATEMIA; IN VITRO STUDY; LETTER; MESENCHYMAL STEM CELL; OSSIFICATION; OSTEOBLAST; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; BONE DEVELOPMENT; CELL CULTURE; CYTOLOGY; DRUG EFFECTS; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEINS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; HUMANS; IN VITRO TECHNIQUES; MESENCHYMAL STROMAL CELLS; OSTEOBLASTS; OSTEOGENESIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; THIAZOLES;

EID: 77954660769     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.84     Document Type: Letter

References (18)

1. O'Sullivan S, Horne A, Wattie D, Porteous F, Callon K, Gamble G et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab 2009;94:1131-1136.
2. Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008;1111:2538-2547.
3. Jonsson S, Olsson B, Ohlsson C, Lorentzon M, Mellstrom D, Wadenvik H. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica 2008;93:1101-1103.
4. Vandyke K, Dewar AL, Farrugia AN, Fitter S, Bik TL, Hughes TP et al. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 2009;23:994-997.
5. Brownlow N, Russell AE, Saravanapavan H, Wiesmann M, Murray JM, Manley PW et al. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Leukemia 2008;22:649-652.
6. Brownlow N, Mol C, Hayford C, Ghaem-Maghami S, Dibb NJ. Dasatinib is a potent inhibitor of tumour-associated macrophages, osteoclasts and the FMS receptor. Leukemia 2009;23:590-594.
7. O'Sullivan S, Naot D, Callon K, Porteous F, Horne A, Wattie D et al. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms. J Bone Miner Res 2007;22:1679-1689.
8. Fierro F, Illmer T, Jing D, Schleyer E, Ehninger G, Boxberger S et al. Inhibition of platelet-derived growth factor receptor beta by imatinib mesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro. Cell Prolif 2007;40:355-366.
9. Gazzerro E, Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 2006;7:51-65.
10. Mariani S, Giona F, Basciani S, Brama M, Gnessi L. Low bone density and decreased inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008;372:111-112.
11. Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE. Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations. Cancer 2009;115:1381-1394.
12. Giles FJ, O'Dwyer M, Swords R. Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia. Leukemia 2009;23:1698-1707.
13. Li B, Boast S, de los SK, Schieren I, Quiroz M, Teitelbaum SL et al. Mice deficient in Abl are osteoporotic and have defects in osteoblast maturation. Nat Genet 2000;24:304-308.
14. Zhao C, Irie N, Takada Y, Shimoda K, Miyamoto T, Nishiwaki T et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 2006;4:111-121.
15. Martin TJ, Allan EH, Ho PW, Gooi JH, Quinn JM, Gillespie MT et al. Communication between EphrinB2 and EphB4 within the osteoblast lineage. Adv Exp Med Biol 2010;658:51-60.
16. Tokunaga A, Oya T, Ishii Y, Motomura H, Nakamura C, Ishizawa S et al. PDGF receptor beta is a potent regulator of mesenchymal stromal cell function. J Bone Mine Res 2008;23:1519-1528.
17. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 2000;151:311-320.
18. Wildes TM, Procknow E, Gao F, Dipersio JF, Vij R. Dasatinib in relapsed or plateau-phase multiple myeloma. Leuk Lymphoma 2009;50:137-140.